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Abstract 
Paradoxically, the thymidine kinase (TK) encoded by Kaposi sarcoma-associated 
herpesvirus (KSHV) is an extremely inefficient nucleoside kinase, when compared to 
TKs from related herpesviruses.  We now show that KSHV-TK, in contrast to HSV1-TK, 
associates with the actin cytoskeleton, induces extensive cell contraction followed by 
membrane blebbing.  These dramatic changes in cell morphology depend on the auto-
phosphorylation of tyrosine 65, 85 and 120 in the N-terminus of KSHV-TK.  
Phosphorylation of Tyrosine 65/85 and 120 results in an interaction with Crk family 
proteins and the p85 regulatory subunit of PI3-Kinase respectively.  The interaction with 
KSHV-TK leads to tyrosine phoshorylation of Crk.   Auto-phosphorylation of KSHV-TK 
also induces a loss of FAK and paxillin from focal adhesions, resulting in activation of 
RhoA-ROCK signalling to myosin II and cell contraction.  In the absence of FAK or 
paxillin, KSHV-TK has no effect on focal adhesion integrity or cell morphology.  Our 
observations demonstrate that by acting as a tyrosine kinase KSHV-TK modulates 
signalling and cell morphology.   
 
 
KSHV / Thymidine kinase / Cell blebbing / RhoA / Focal adhesion / Crk/PI3-Kinase 
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Introduction 
Kaposi sarcoma-associated herpesvirus is a gammaherpesvirus that is the causative 
agent of several human cancers including primary effusion lymphoma (PEL), the 
plasmablastic variant of multicentric Castleman's disease (MCD), and Kaposi's sarcoma 
(KS) (Cesarman et al, 1995; Chang et al, 1994; Moore et al, 1996; Soulier et al, 1995). 
In pre-existing HIV infections, secondary KSHV infection induces a high incidence of 
Kaposi's sarcoma development, demonstrating the potent oncogenic capacity of this 
human virus (Martin et al, 1998).  The selective inhibition of KSHV encoded enzymes 
that are essential for viral replication may therefore provide good therapeutic targets to 
limit the impact of KSHV infection and disease progression.   
 
Herpes viruses encode a variety of enzymes that are essential for their replication, 
including a Thymidine kinase (TK) that overcomes a rate-limiting step during viral DNA 
replication in non-cycling cells by phosphorylating thymidine (Chen et al, 1979). TK-
deficient Herpes virus simplex virus (HSV) is avirulent because it no longer replicates in 
terminally differentiated neurons (Coen et al, 1989; Efstathiou et al, 1989; Valyi-Nagy et 
al, 1994). Additionally, pathogenesis studies with Murid Herpesvirus-4 (MuHV-4), a close 
relative of KSHV, have also shown that its TK is required for lytic replication in mice 
(Coleman et al, 2003). The fact that MuHV-4 lacking its thymidine kinase fails to infect 
via the upper respiratory tract argues that the TK is required for viral replication in a cell 
limited for nucleotides (Gill et al, 2009).  The pivotal role of these viral nucleoside 
kinases for in vivo replication makes them good targets for anti-viral therapeutics.  
 
The design of acyclovir, a nucleoside analogue that is selectively phosphorylated by the 
thymidine kinase of HSV, and subsequently inhibits the viral DNA polymerase, is a prime 
example of how viral enzymes can be selectively targeted to prevent viral DNA 
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replication (Elion, 1982; Field & Biron, 1994; Smee et al, 1983). Additionally, the 
effectiveness of nucleoside analogues such as Cidofovir at reducing pathologies 
associated with MuHV-4 infection suggests that the TK of KSHV may represent a 
potential target to limit lytic replication of the virus and subsequent disease (Dal Canto et 
al, 2000; Gangappa et al, 2002; Neyts & De Clercq, 1998; Staskus et al, 1997).  
 
A key point in devising anti thymidine kinase-based therapies is to understand exactly 
how each enzyme functions.  In contrast to other herpes viruses, the TKs encoded by 
gamma-herpesviruses consist of a unique N-terminal domain linked to a catalytic C-
terminal kinase domain (Holton & Gentry, 1996; Littler & Arrand, 1988; Littler et al, 
1986).  They are also very inefficient thymidine kinases (Gustafson et al, 1998; 
Gustafson et al, 2000).   For example, the thymidine kinase of KSHV has a ~ 60 fold 
higher Km for thymidine than that of HSV1 (Gustafson et al, 2000).  Of those studied to 
date, the TKs encoded by gamma-herpesviruses, unlike that of HSV1, are also not found 
in the nucleus (Degreve et al, 1998; Gill et al, 2007; Gill et al, 2005). Gamma2 
herpesvirus TKs, such as those encoded by KSHV, rhesus monkey rhadinovirus, herpes 
saimiri and MuHV-4, are also phosphorylated on tyrosine residues in their N-terminal 
domain (Gill et al, 2005).  Tyrosine phosphorylation of other viral TKs has not been 
observed (Gill et al, 2005).  KSHV, unlike MuHV-4 and EBV, also encodes a thymidylate 
synthetase that can generate thymidine 5’-monophosphate via an alternative route 
independent of TK (Gaspar et al, 2002).  The TK encoded by KSHV may therefore 
possess other functions that can be more effectively used by the virus during replication.  
Such a precedent has been reported for a number of nucleoside metabolism enzymes 
captured by viruses that have acquired new cellular functions (Davison & Stow, 2005; 
Gaspar et al, 2008; Lembo et al, 2004).  
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Previous observations suggest that KSHV TK, which associates with unknown structures 
throughout the cytoplasm is capable of inducing cell rounding (Gill et al, 2005).  In this 
study we set out to address how this viral thymidine kinase induces such morphological 
changes.  We find that KSHV-TK is a tyrosine kinase that when auto-phosphorylated 
disrupts the integrity of focal adhesions and induces activation of Rho-ROCK-Myosin II 
dependent cell contraction and blebbing. Moreover, our results suggest that KSHV TK is 
a potential target for the development of tyrosine kinase inhibitors to limit its impact upon 
cell signalling pathways during lytic replication, to contribute to the treatment of virus-
induced pathologies such as Kaposi sarcoma.     
 
Results 
KSHV-TK induces cell contraction and blebbing 
Previous work reveals that KSHV-TK induces cell rounding and detachment of adherent 
cells (Gill et al, 2005). To obtain additional insights into these morphological changes we 
analyzed the effects of expressing GFP-tagged KSHV-TK (GFP-KSHV-TK) on cell 
morphology using time-lapse microscopy. Cells expressing GFP-KSHV-TK initially had a 
flat epithelial morphology but were observed to undergo a dramatic contraction ~ 16 
hours post-transfection (Figure 1A; Movies S1 and S2). Expression of GFP-KSHV-TK in 
COS-7 and BHK-21 cells resulted in a similar phenotype (Figure S1A).  In contrast, 
expression of GFP-tagged HSV1-TK had no effect on cell shape or obvious changes in 
focal adhesion integrity as discussed later (Figure S1B).    
 
Closer examination reveals that GFP-KSHV-TK expressing cells that had contracted 
underwent extensive membrane blebbing (Figure 1B; Movie S3). The morphological 
changes observed in time-lapse studies were also evident in the scanning electron 
microscope (Figure 1C). GFP-KSHV-TK induced membrane blebbing was not due to 
  Gill et al., 2014 KSHV-TK 
 6 
apoptosis as cells remained viable as they excluded trypan blue.  They also showed 
none of the hallmarks of apoptosis when examined in the transmission electron 
microscope (Figure S1C). Consistent with this, the apoptosis inhibitor Z-ZAD-FMK did 
not prevent GFP-KSHV-TK induced cell contraction (Figure S1D).   
 
KSHV-TK induced contraction is dependent on RhoA, ROCK and Myosin II 
Prior to cell contraction GFP-KSHV-TK forms an extensive array of filaments, a 
proportion of which align with a subset of actin stress fibres (Figure 1D).  It was also 
noticeable that GFP-KSHV-TK also promoted an increase in the number of central actin 
stress fibres in spread cells before they contracted (Figures 1D and S1E). To examine 
how KSHV-TK induces actin stress fibre formation, we examined the consequences of 
inhibiting RhoA signalling via ROCK to myosin II, the major signalling pathway involved 
in their formation (Pellegrin & Mellor, 2007).  We found that co-expression of the 
dominant negative GFP-RhoN19 mutant partially inhibited the ability of RFP-KSHV-TK to 
promote cell contraction (Figure 2A).  Treatment of cells with Y-27632 or Blebbistatin, 
which inhibit ROCK and myosin II respectively, also abrogated KSHV-TK induced stress 
fibre formation and cell contraction (Figure 2B). Treatment of cells with Y-27632 or 
Blebbistatin, in the absence of KSHV-TK, did not alter the integrity of focal adhesions 
(Figure S2A). Consistent, with these observations we found that the level of GTP-bound 
RhoA is higher in GFP-KSHV-TK expressing cells (Figure 2C).  
 
KSHV-TK disassembles focal adhesions  
The dramatic changes in morphology induced by KSHV-TK are indicative of a possible 
alteration in the interaction of the cell with the extracellular substrate. To explore this 
possibility, we examine whether KSHV-TK induces changes in the composition and/or 
integrity of focal adhesions.  We found that there was a reduction in the normal 
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phosphotyrosine staining of focal adhesions in cells expressing GFP-KSHV-TK (Figure 
2D).  The reduction in phoshotyrosine signal at focal adhesions, however, was not 
always readily apparent as it was frequently masked by a strong phoshotyrosine signal 
associated with KSHV-TK (Figure 2D).  To overcome this problem, we used phospho 
specific antibodies to examine the level of tyrosine phosphorylated FAK and paxillin at 
focal adhesions in cells expressing KSHV-TK (Figures 2D and S2B). 
Immunofluorescence analysis with antibodies against phosphorylated tyrosine 397, 861 
and 925 of FAK reveals that level of activated phospho-FAK associated with focal 
adhesions is lower in cells expressing GFP-KSHV-TK (Figures 2D and S2B).  A similar 
reduction in the level of phospho-paxillin was observed using antibodies directed at 
phosphorylated tyrosine 31 and 118 of paxillin (Figures 2D and S2B). Quantification 
reveals that in cells expressing GFP-KSHV-TK the phospho-Paxillin-Y31 and phospho-
FAK-Y925 signal associated with focal adhesions was reduced by 84.4% and 67.23% 
respectively compared to GFP alone (Figure S2C).  Consistent, with its inability to 
induce cell contraction, expression of GFP-HSV1-TK did not induce a loss in the 
phosphotyrosine or phospho-paxillin signal at focal adhesions or stimulate actin stress 
fibre formation (Figure S1).    
 
Not only did KSHV-TK induce the loss of the phospho FAK and paxillin signal associated 
with focal adhesions it also altered the cellular distribution of total FAK and paxillin 
(Figure S3A). Staining for other focal adhesion components including Parvin, VASP, 
Vinculin and Zyxin revealed a similar reduction at focal adhesions together with an 
increase in the cytoplasmic level of the protein (Figures S3A, B).  The ability of KSHV-TK 
to induce loss of focal adhesion integrity was identical regardless of whether the protein 
was tagged with GFP, RFP or not (Figure S3C).    
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Virally expressed KSHV-TK also induces disassembly of focal adhesions  
To confirm our observations in transfected cells we sought to analyse the effect of 
KSHV-TK expression on focal adhesion integrity during lytic viral replication.  As it is still 
not possible to assess the role of specific KSHV encoded proteins during lytic replication 
using the KSHV BAC mutagenesis system, we generated a recombinant MuHV-4 virus 
in which KSHV-TK was substituted for the TK of this closely related gamma herpesvirus 
(Figure 3A).  This is possible as the MuHV-4 TK is essential for in vivo replication, but is 
dispensable for replication in cell culture (Coleman et al, 2003).  The resulting 
recombinant virus is denoted MuHV-4 [g-KSHV-TK] (Figure 3A).  Cells infected with 
MuHV-4 [g-KSHV-TK] expressed GFP-KSHV-TK, which became tyrosine 
phosphorylated (Figure 3B). The recombinant virus also had similar early and late lytic 
protein expression as the parental MuHV-4 (Figure S4A). Infection with MuHV-4 [g-
KSHV-TK] induced a similar loss of the phospho-FAK Y925 and phospho-Paxillin Y31 
signal associated with focal adhesions as observed in cells expressing GFP-KSHV-TK 
(Figure 3C). In contrast, infection with MuHV-4 had no affect on focal adhesion integrity 
or distribution of phospho-FAK or phospho-Paxillin (Figure 3C). The cell rounding 
observed in cells infected with the recombinant MuHV-4 (MuHV-4, g-KSHV-TK), 
expressing KSHV-TK, could be blocked by the inclusion of the ROCK inhibitor Y-27632 
during viral replication (Figure 3D).    
 
In addition, although lytic replication is very inefficient in culture we took advantage of 
two available systems to examine the impact of lytic KSHV replication on cell 
morphology. In one approach, Vero cells containing latent KSHV (rKSHV.219) (GFP+ 
cells) were induced to promote lytic replication, which can be observed by the 
expression of RFP that is driven by a pan-lytic KSHV promoter (Vieira & O'Hearn, 2004). 
Cells in which lytic replication was visible (GFP+/RFP+) were clearly contracted, 
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compared to cells with latent virus (GFP+) which retained a more flattened morphology 
(Figure 3E). The cell rounding observed during KSHV lytic replication could also be 
blocked by the incubation of Y-27632 (Figure 3E). In the second experimental approach 
virus was generated from a recombinant KSHV-Lyt virus that constitutively expresses 
the main lytic switch regulator, RTA (Budt et al, 2011). Filtered supernatants containing 
KSHV-lyt were then used to infect HeLa cells in the absence or presence of Y-27632. In 
the absence of Y-27632, infected cells (GFP+) underwent cell contraction and had a 
strong phospotyrosine staining (Figure S4B). In the presence of Y-27632 the infected 
cells maintained a more flattened morphology (Figure S4B).   Taken together our data 
clearly show that the ROCK specific inhibitor Y-27632 is sufficient to block the cell 
rounding induced by KSHV-TK in over expression and viral contexts, including KSHV 
lytic replication.  
 
Cell contraction is dependent on auto-phosphorylation of KSHV-TK 
Immunofluorescence and western blot analysis reveals that KSHV-TK is clearly tyrosine 
phosphosphorylated (Figures 2D and 3A).  To examine if the catalytic activity of KSHV-
TK is responsible for its auto-phosphorylation and whether this modification is required 
to induce cell contraction, we generated a kinase dead mutant (KSHV-TK-DEAD) by 
changing three essential glycine residues in the ATP binding motif of the kinase domain 
to Alanine (Saraste et al, 1990).  Immunoblot analysis reveals that KSHV-TK-DEAD has 
a dramatic reduction in its level of tyrosine phosphorylation (Figure 4A).  Moreover, in 
contrast to the wild type protein, KSHV-TK-DEAD is diffuse in the cytoplasm and does 
not form a reticular network, nor does it induce cell contraction or blebbing (Figures 4A, 
B). Immunofluorescence analysis of the distribution of FAK, Parvin, Paxillin, VASP, 
Vinculin and Zyxin also indicated there were no obvious changes in the integrity of focal 
adhesions (compare Figures 4C, 4D and S5 with Figures 2D, S2B and S3A).   
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To further validate the ability of KSHV-TK to act as a tyrosine kinase and auto-
phosphorylate itself, we expressed and purified the protein from E. coli.  The EBV and 
MuHV-4 related gammaherpes TKs were used as controls.  Immunoblot analysis reveals 
that in contrast to the TKs from EBV and MuHV-4, KSHV-TK is tyrosine phosphorylated 
when purified from E. coli (Figure 4E).  The ability of purified recombinant KSHV-TK to 
undergo auto-phosphorylation in the presence of ATP after treatment with protein 
tyrosine phosphatase 1B (PTP1B) further confirmed its tyrosine kinase activity (Figure 
4E). Furthermore, the auto-phosphorylation of KSHV-TK was abolished when the kinase 
dead mutant was purified from E. coli (Figure 4F).  By expressing the individual domains 
of KSHV-TK in mammalian cells, we could also demonstrate that the N-terminal region 
of KSHV-TK is only phosphorylated when attached to its C-terminal kinase domain 
(Figure 4G).  
 
To investigate whether the loss of focal adhesion integrity is due to phosphorylation of 
KSHV-TK or phosphorylation of cellular targets, we set out to define which tyrosine 
residues are auto-phosphorylated in KSHV-TK.  Western blot analysis of a series of N-
terminal deletion mutants reveals that auto-phosphorylation of KSHV-TK is lost when the 
first 100 amino acids of this protein are removed (Figure 5A). Motif searches in the first 
100 amino acids with the Scansite server (scansite.mit.edu/motifscan_seq.phtml) predict 
that when phosphorylated, tyrosine residues 65 and 85 of KSHV-TK are potential SH2 
binding sites for a number of proteins. Given, this we mutated each tyrosine residue to 
phenylalanine, alone or in combination to examine their contribution to KSHV-TK 
induced focal adhesion disassembly.  Western blot analysis revels that the single 
tyrosine mutants (Y65F, and Y85F) are still phosphorylated (Figure S6A).  The single 
mutants also induced loss of focal adhesion integrity and cell rounding that was 
  Gill et al., 2014 KSHV-TK 
 11 
indistinguishable from the wild type protein (Figure S6B).  In contrast, the double mutant 
(denoted as Y2F) had significantly reduced auto-phosphorylation and did not induce cell 
rounding or changes in focal adhesion integrity (Figure S6B, C).  These results suggest 
that auto-phosphorylation of tyrosine 65 and 85 of KSHV-TK is sufficient to disrupt focal 
adhesion integrity and induce cell contraction. To confirm that KSHV-TK auto-
phosphorylates tyrosine 65 and 85 we performed Mass spec analysis of KSHV-TK 
purified from E. coli. (Figure S7). This analysis confirmed tyrosine 65 and 85 are 
phosphorylated and also revealed that tyrosine 120 is additionally modified (Figure S7). 
Phosphorylation of tyrosine Y120 of KSHV-TK is also consistent with the partial 
phosphorylation of the Y2F mutant  (Figures 5B  and S6A).   Mutation of tyrosine 120 in 
conjugation with Y65 and Y85 completely abolished tyrosine phosphorylation of KSHV-
TK (Figure 5B). Cells expressing the triple mutant Y65/85/120F (denoted as Y3F) were 
indistinguishable from controls as they had a flat morphology and prominent focal 
adhesions (Figure 5C-E). Consistent with this, the KSHV-TK DEAD, Y2F and Y3F 
mutants failed to increase the level of GTP bound RhoA induced by the wild type protein 
(Figure 5F). In order to examine the impact of expressing the KSHV-TK-Y3F during lytic 
viral replication we generated a recombinant MuHV-4 virus.  In contrast to the cell 
rounding induced by KSHV-TK, the MuHV-4 infected cells expressing KSHV-TK-Y3F 
retained a flat morphology (Figure 5G).  
 
The kinase activity of KSHV-TK is required for its association with FAK 
Expression of KSHV-TK leads to a loss of phospho-paxillin at focal adhesions (Figure 
2D).  Phosphorylation of paxillin at focal adhesions is mediated by a complex of FAK-Src 
(Frame, 2004; Glenney & Zokas, 1989; Schaller & Parsons, 1995; Schlaepfer & Mitra, 
2004).  It is possible that the KSHV-TK kinase activity disrupts the ability FAK-Src to 
phosphorylate paxillin. Consistent with this, the ability of KSHV-TK to associate with FAK 
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was dependent upon its kinase activity, as the KSHV-TK-DEAD but not the Y2F or Y3F 
mutants failed to associate with FAK (Figure 6A). To further define the contribution of 
FAK and paxillin in the KSHV-TK induced phenotypes, we examined the effects of 
expressing GFP-KSHV-TK on the localization of paxillin and zyxin in FAK-/- or paxillin 
depleted cells.  In FAK-/- but not FAK+/+ cells, both paxillin and zyxin were readily 
detected in peripheral focal adhesions and the cells did not undergo contraction (Figures 
6B and S6D).  Immunofluorescence analysis reveals that RNAi mediated depletion of 
paxillin did not inhibit tyrosine phosphorylation of GFP-KSHV-TK, which still forms an 
extensive array of filaments throughout the cell (Figure 6C).  The loss of paxillin, 
however, did prevent GFP-KSHV-TK induced disassembly of focal adhesions and cell 
contraction (Figure 6C).  Our observations clearly demonstrate that KSHV-TK mediated 
focal adhesion disassembly and cell contraction involves FAK and paxillin.    
 
KSHV-TK interacts with Crk family members and the p85 subunit of PI3-kinase 
We set out to identify cellular binding partners for phosphorylated tyrosine 65 and 85 
given their absolute requirement in KSHV-TK induced cell contraction. Upon closer 
examination we realised that Y65 (pYDVP) and Y85 (pYATP) matched the preferred Crk 
SH2 binding motif of pY-x-x-P (Figure 7A) reviewed in (Birge et al, 2009). 
Immunoprecipitation of GFP-KSHV-TK and its Y2F mutant reveals that endogeneous 
CrkI, CrkII and CrkL interact with the wildtype protein but not with the Y2F mutant lacking 
tyrosines 65 and 85 (Figure 7B).  Immunofluorescence analysis, also reveals that 
endogeneous CrkII associates with KSHV-TK but not the Y2F mutant (Figure 7C).  To 
confirm KSHV-TK interacts with the SH2 domain of CrkL and CrkII we performed pull 
down assays on cells co-expressing different GFP-tagged CrkL and CrkII domains.  We 
found that RFP-KSHV-TK only interacts with the SH2 domain of CrkL and CrkII (Figure 
  Gill et al., 2014 KSHV-TK 
 13 
7D). In addition, the co-expression of either the SH2 of CrkII or CrkL was sufficient to 
block RFP-KSHV-TK induced cell rounding (Figure 7E).  
 
Interestingly, tyrosine 120 of KSHV-TK conforms to the preferred PI3-Kinase SH2 
binding motif of pY-x-x-M (Figure 8A)(Songyang et al, 1993).  Immunoblot analysis of 
GFP immunoprecipitations reveals that in contrast to the wild type protein and the Y2F 
mutant, KSHV-TK-Y120F has a significantly reduced interaction with endogeneous p85 
regulatory subunit of PI3K (Figure 8B). Furthermore, immunoprecipitations demonstrate 
that CrkII and/or CrkL are unable to interact with KSHV-TK via an association with PI3K 
(Figure 8C, D).  This suggests that the two pathways downstream of phosphorylated 
tyrosine 65/85 and 120 are operating independently from each other. 
 
KSHV-TK induces phosphorylation of Crk bound to tyrosines 65 and 85  
Given that tyrosine phosphorylation of Crk family proteins impacts on their cellular 
function (reviewed in (Birge et al, 2009), we decided to see if KSHV-TK induces 
phosphorylation of CrkII and CrkL on tyrosine 221 and 207 respectively (Figure 7D).   
Immunoblot analysis with phospho-specific antibodies on endogeneous CrkII and CrkL 
immunpopreciptiated from cells expressing GFP-KSHV-TK reveals that both proteins 
become phosphorylated in the presence of the viral kinase (Figure 8E).  Increased 
tyrosine phosphorylation of CrkII and CrkL was not observed in cells expressing the 
GFP-KSHV-TK Y2F or Y3F mutants (Figure 8E).  This suggests that the interaction of 
CrkII and CrkL with Tyrosine 65/85 of KSHV-TK is required for their phosphorylation.  
The Y2F result also provides further evidence that the two signalling pathways act 
independently, as the presence of PI3K bound to KSHV-TK does not enhance CrkII or 
CrkL phosphorylation.  To confirm this is the case, we examined the ability of 
recombinant His-CrkII to bind and be phosphorylated by GFP-KSHV-TK.   We found that 
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the wild type but not the Y2F or Y3F mutants could bind and phosphorylate His-CrkII 
(Figure 8F).  Furthermore, the interaction of His-CrkII is specific for phosphorylated 
tyrosine 65/85 as in the presence of phosphorylated tyrosine 120 in the Y2F mutant 
there was still no binding (Figure 8F).  Taken together our results indicate that Crk family 
members and PI3K are acting independently of each other downstream of phospho-
tyrosine 65/85 and 120 respectively. 
 
Discussion  
One of the most successful anti-viral therapeutics used to limit herpesvirus replication, 
has been the design of inhibitory nucleoside analogues, such as acyclovir and 
gancyclovir, that are specifically phosphorylated by the virus encoded thymidine kinase 
and block viral DNA replication (Elion, 1982; Elion, 1993; Galarraga et al, 2005; Reardon 
& Spector, 1989; Sia & Patel, 2000; Smee et al, 1985).  Based on the conservation of 
their kinase domains one would assume that the TK expressed by the 
gammaherpesvirus KSHV would represent a favourable target for nucleoside analogue 
directed therapies. However, previous studies have shown that the thymidine kinase 
encoded by KSHV is an extremely inefficient enzyme compared to related herpesvirus 
TKs (Gustafson et al, 2000).  Moreover, the ability of the TK from KSHV but not that of 
HSV1, to induce cell rounding when expressed in mammalian cells suggested that the 
two kinases may have very different functions during infection (Gill et al, 2005).  In trying 
to understand how KSHV-TK induces cell contraction, we have now uncovered that the 
protein is actually a tyrosine kinase that auto-phosphorylates tyrosine 65, 85 and 120 in 
its N-terminal domain.  Phosphorylation of tyrosines 65 and 85 of KSHV-TK ultimately 
leads to the loss of focal adhesion integrity and the induction of cell contraction followed 
by blebbing.  These KSHV-TK induced morphological changes are dependent on FAK 
and paxillin as well as the activity of RhoA-ROCK signalling to myosin II.   
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It is well established that Paxillin is a pivotal player in the formation of focal adhesions 
(Turner, 2000). Once recruited to the leading edge of migrating cells, paxillin becomes 
tyrosine phosphorylated by a complex of FAK-SRC and acts as a scaffolding protein to 
recruit both structural and signalling proteins to the developing focal adhesion (Burridge 
et al, 1992; Laukaitis et al, 2001; Nakamura et al, 2000; Nikolopoulos & Turner, 2000). In 
this study we have demonstrated that KSHV-TK leads to a loss of paxillin 
phosphorylated on tyrosines 31 and 118 at focal ahesions. This presumably results from 
the ability of catalytically active KSHV-TK to bind to and interfere with the normal cellular 
functionality of FAK-SRC. When phosphorylated tyrosines 31 and 118 of paxillin bind 
directly to the SH2 domain of p120RasGAP preventing its interaction with p190RhoGAP, 
which in turn leads to the suppression of RhoA signalling at focal adhesions (Iwasaki et 
al, 2002; Tsubouchi et al, 2002).  Our observations suggest that KSHV-TK induces cell 
contraction and blebbing by indirectly activating RhoA signalling to Myosin II by 
disrupting the ability of FAK-Src to phosphorylate tyrosine residues 31 and 118.  
Consistent with this, FAK deficient cells expressing KSHV-TK do not undergo 
contraction and focal adhesion disassembly. However, the ability of FAK to still interact 
with the phosphorylation deficeint Y3F KSHV-TK mutant, suggests an additional cellular 
protein(s), presumably upstream of FAK or in addition to FAK, that enables KSHV-TK to 
induce focal adhesion dissassembly and cell contraction.  
 
We have now found that when phosphorylated tyrosine 65 and 85 of KSHV-TK interact 
with the SH2 domain of Crk family proteins. Crk family members are potent oncogenic 
SH2/SH3 adaptor proteins that play a critical role in regulating cell adhesion through the 
formation of a diverse array of signalling complexes (Birge et al, 2009). Crk family 
members bind to phosphorylated paxillin and p130Cas via their SH2 domain, and in 
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doing so partially protect these proteins from dephosphorylation by cellular 
phosphatases (Iwasaki et al, 2002; Schaller & Parsons, 1995; Takino et al, 2003) . In the 
case of paxillin, phosphorylation of Y31 and Y118 is sufficient to prevent RhoA activation 
(Tsubouchi et al, 2002).  Crk family members also bind to Rho-GTPase exchange 
factors DOCK180, SOS1 and C3G via their N-terminal SH3 domain (Birge et al, 2009). 
The formation of Cas-Crk-C3G complex promotes cell adhesion and spreading resulting 
from Rap1 activation (Sakakibara et al, 2002). In contrast, Paxillin-Crk-DOCK180 and 
Paxillin-CrkII-GIT2/PKL--PIX complexes promote Rac1 activation and cell spreading 
(Ichiba et al, 1999; Lamorte et al, 2003; Valles et al, 2004). The strong association of 
CrkII with KSHV-TK filaments suggests that the viral kinase is sequestering Crk family 
proteins away from their normal cellular binding partners including phosphorylated 
Paxillin. The sequestering activity immediately suggests KSHV-TK induces activation of 
RhoA and cell contraction by blocking the formation of Crk signalling complexes involved 
in promoting or maintaining cell spreading.  In addition, KSHV-TK also increased the 
phosphorylation of CrkII and CrkL on tyrosine residues 221 and 207 respectively, a 
modification that promotes an auto-inhibited conformation for both proteins (reviewed in 
(Birge et al, 2009)). In its auto-inhibited state, the Crk N-terminal SH3 domain is also 
unable to interact with GEFs including DOCK180 and C3G. Failure of C3G to bind Crk 
inactivates Rap1 and consequently stimulates RhoA activation (Huang et al, 2008), a 
state reminiscent of that induced by KSHV-TK.  
 
When phosphorylated tyrosine 120 of KSHV-TK binds to the p85 regulatory subunit of 
PI3-Kinase, although the biological significance of this interaction remains to be defined. 
Intriguingly, we do not see any association between Crk family members and the p85 
subunit of PI3-K in the absence of KSHV-TK expression. The ability of phosphorylated 
KSHV-TK to form a complex with both Crk and pI3-K p85 is reminiscent of that observed 
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when tyrosine phosphorylated Cbl forms a complex with both Crk and pI3-K p85 in 
activated T cells (Gelkop et al, 2001). In activated T lymphocytes C3G is believed 
displaced from the Crk-Cbl-C3G complex enabling the formation of the Crk-Cbl-PI3-K 
p85 complex (Gelkop et al, 2001). C3G is known to activate Rap1, block Ras-dependent 
signalling, and in doing so promote immune cell anergy (Boussiotis et al, 1997; Moodie 
et al, 1993). The ability of KSHV-TK to simultaneously bind to both Crk and PI3-K p85 
could also block C3G binding to Crk and represent a platform for further Crk and PI3-K 
p85 signalling.  
 
Unfortunately, in the absence of an animal model, it is currently not possible to examine 
the cellular consequences of KSHV-TK expression in vivo or its contribution to KSHV 
pathogenesis.  We have found that expression of KSHV-TK alone or in the context of 
infection with a recombinant MuHV-4 induces cell contraction and persistent blebbing. 
Lytically replicating KSHV was also capable of promoting ROCK dependent cell 
rounding.  However understanding the precise contribution of KSHV-TK phosphorylation 
to viral replication and spread will only be possible once a better lytic KSHV replication 
system is available that permits the generation of site specific mutants, which at present 
are currently unavailable.  
 
In recent years, it has become clear that cell blebbing is an important aspect driving the 
migration of embryonic and tumour cells in 3D environments (Charras & Paluch, 2008; 
Fackler & Grosse, 2008; Lammermann & Sixt, 2009; Paluch & Raz, 2013; Sahai & 
Marshall, 2003).  As in the case of KSHV-TK, these cellular blebs are induced via the 
activation of RhoA-ROCK signalling to Myosin II.  Bleb induced matrix deformation 
followed by reattachment enables cancer cells to move in an amoeboid-like fashion 
through the extra-cellular matrix without the requirement for proteases (Pinner & Sahai, 
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2008; Tozluoglu et al, 2013).  Based on our observations, we suggest that expression of 
KSHV-TK early during lytic replication will induce changes in the interaction of infected 
cells with both their non-infected neighbours and the extracellular matrix.  It is also 
possible that KSHV-TK promotes infected cell migration in a manner analogous to that 
observed for tumour cells potentially by modulating the functionality of Crk family 
members and/or FAK-Src signalling via paxillin. Inducing migration of infected cells may 
provide a selective advantage during viral pathogenesis, as it will enhance the spread of 
infection independently of virus shedding.  Moreover, endothelial cells, which are 
believed to be the source of Kaposi’s sarcoma spindle cells (Hong et al, 2004) are also 
capable of moving via cell blebbing (Norman et al, 2010).  It is possible that TK mediated 
activation of RhoA during lytic virus replication, potentially via paxillin dephosphorylation 
and Crk phosphorylation, promotes the movement of these cells.  The latter would assist 
in seeding KSHV infected cells to new anatomical sites for establishment and replication, 
consistent with the multi focal vascular nature of Kaposi’s sarcoma.  The use of RhoA 
activation to promote cell movement contrasts the situation for vaccinia virus, where the 
viral protein F11 enhances the spread of infection by inducing cell migration and 
modulating the integrity of the cortical actin by binding RhoA to inhibit its downstream 
signalling (Arakawa et al, 2007a; Arakawa et al, 2007b; Cordeiro et al, 2009; Handa et 
al, 2013; Valderrama et al, 2006).  
 
It is currently unclear how KSHV-TK autophosphorylates itself since its lacks a classical 
tyrosine kinase signature.  Unfortunately, no structure of either the catalytic domain or a 
full-length gammaherpesvirus TK has been determined.  The structure of KSHV-TK or its 
kinase domain will undoubtedly provide important mechanistic insights into how this viral 
nucleoside kinase acts as a protein tyrosine kinase. It will also help facilitate the rational 
design of drugs to inhibit this viral kinase that has generally been overlooked but which 
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should now be added to the list of potent signalling proteins expressed by KSHV.  It will 
now be important to analyse the impact of KSHV-TK in vivo in order to assess its true 
oncogenic capacity and identify specific inhibitors that block the cellular effects of this 
viral kinase.  In summary our analysis suggest that KSHV-TK represents a new potential 
drug target for with which to potentially limit the dissemination of lytically replicating cells 
infected with KSHV.  
 
Materials and methods  
Expression Plasmid  
KSHV TK (ORF21) was amplified and cloned into pEGFPC2 (Clontech), pCherryC2 (a 
generous gift of Dr. C. Crump, Cambridge, UK) or pcDNA3.1 (-) (Invitrogen).  The 
pEGFPC2 (or pCherryC2)-KSHV TK-DEAD were generated by PCR-based mutagenesis 
using the following primers 5’gctttacttagaggcggtaatggctgtggccaaatcaacgctggtcaac3’ and 
5’gttgaccagcgttgatttggccacagccattaccgcctctaagtaaagc3’, which change glycines 260, 
263 and 265 to alanine residues in the ATP binding site.  The KSHV-TK Tyrosine to 
Phenylalainine mutants were generated using the following primers using site directed 
mutagenesis: Y65F (5’gtaaaaacctcgtacatatttgacgtggcccaccgtcccga3’) and 
(5’tcgggacggtgggccacgtcaaatatgtacgaggtttttac3’), Y85F 
(5’tgcacgacaactccctctttgcaacgcctaggtttccgcc3’) and 
(5’ggcggaaacctaggcgttgcaaagagggagttgtcgtgca3’), Y120F 
(5’tgacgacgactcgggagactttgcgccaatggatcgcttc3’) and 
(5’gaagcgatccattggcgcaaagtctccgagtcgtcgtca3’). The pEGFPC2 KSHV-TK N-terminal 
truncation clones were generated as previously (Gill et al, 2005). 
 
Full length FAK was amplified cloned into pEGFPC2 to generate pEGFPC2-FAK.  
Paxillin was amplified cloned into pEGFPN2  to generate pEGFPN2-Paxillin. ORFs 
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encoding EBV-TK, MuHV-4-TK and KSHV-TK (and KSHV-TK-DEAD) were cloned into 
pGEX4T1 (Invitrogen) in frame and downstream of GST. CrkII and CrkL and 
subdomains (SH2, nSH3, cSH3, plus linker region+cSH3 for CrkL) were amplified cloned 
into pEGFPC2.  
 
Cell lines and drugs 
HeLa, COS-7, BHK, hTERT-RPE1, FAK+/+ and FAK-/- (Ilic et al, 1995) cells and the cre-
transduced derivative 3T3-CRE (Stevenson et al, 2002) were grown in Dulbecco's 
modified Eagle medium (In Vitrogen Corporation) supplemented with 2 mM glutamine, 
100 U/ml penicillin, 100µg/ml streptomycin and 10% fetal calf serum (PAA Laboratories, 
Linz, Austria). For FAK+/+ and FAK-/- cells media was also supplemented with non-
essential amino acids (PAA) and 50M 2-Mercaptoethanol (GIBCO).  Cells were treated 
with 20µM Y-27652 (Calbiochem), 10µM Blebbistatin (Sigma) or 20µM Z-VAD-FMK 
(Promega) 1 h post-transfection and maintained through the transfection in freshly 
added media.  
 
siRNA treatments  
HeLa cells were plated at 5x104 cells per well and were transfect with 100nM total siRNA 
in OptiMEM (Invitrogen) using Dharmafect 1 (Thermo Scientific) according to 
manufacturer’s instructions.  Both a Paxillin siRNA pool (catalogue no. 1027416 
(Qiagen) or mock siRNA (sense AUUCUAUCACUAGCGUGACUU/antisense 
GUCACGCUAGUGAUAGAAUUU) (Thermo Scientific) were used to transfect HeLa 
cells.  Thirty hours after siRNA addition the cells were transfected with the pEGFPC2-
KSHV TK using TransIT-LT1 in accordance with the manufacturers instructions (Mirus). 
Eighteen hours later the cells were either harvested to generate cell lysates, or fixed 
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using 4%PFA for immunofluoresence.  Cell lysates were generated as stated below and 
analysed by SDS-PAGE and immuno-blotting (as described below).  
 
RhoA GTP pull down assays    
1x107 HeLa cells were transfected with GFP, GFP-KSHV-TK, GFP-KSHV-TK mutants 
(DEAD or Y6585F), or mock challenged using Lipofectamine in accordance with the 
manufacturers instructions (Invitrogen). Cell lysates were generated 12 hours after the 
initial transfection in 1ml using 1X MLB buffer. 500l cell lysate was added to 23.1l 
(30g) of Rho Assay Reagent (Rhotekin RBD, agarose)(Millipore, catalogue no. 14-383). 
The mixture was incubated for 45 min at 4oC with gentle agitation. The agarose beads 
were pelleted (10 sec, 14, 000xg, 4oC).  The beads were washed 3X with MLB and then 
resuspended in 40l of 2X laemmli reducing buffer, plus 2l of dithiothreitol and boiled 
for 5 minutes.  The precipitated material was analysed by western blot analysis for 
bound RhoA using RhoA using mAb sc-418 (Santa Cruz) (as described below). Input 
lysates were included as a control.    
  
Electron microscopy    
HeLa cells expressing GFP, GFP-KSHV-TK or GFP-KSHV-TK-DEAD were processed 
for both transmission and scanning electron microscopy as previously described (Bruce 
et al, 2010).  All samples were prepared and processed by the University of Cambridge 
Multi-Imaging Centre.  
 
Immunofluorescence and antibodies 
HeLa, BHK-21 or COS cells grown on glass coverslips were transfected using 
LipofectamineTM-2000 in accordance with the manufacturers instructions or infected with 
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0.5 or 1 p.f.u. / cell of MuHV-4 (wild type), MuHV-4 TK-, MuHV-4 TK Revertant (Coleman 
et al, 2003) or MuHV-4 [g-KSHV-TK]. 16-18 post-transfection/infection cells were fixed 
(4% paraformaldehyde, 20 min), permeabilised (0.1% Triton X-100/PBS, 15 min) and 
blocked (3% bovine serum albumin in PBS/0.1% Tween [T-PBS], 1h).  Primary 
antibodies were incubated in 3%BSA/T-PBS for 1h.  The following primary antibodies 
were used: Phospho-tyrosine (PY99, sc-7020, Santa Cruz), Phospho-FAK Y397 
(ab4803, Abcam), Phospho-FAK Y861 (ab4804, Abcam), Phospho-FAK Y925 (ab38512, 
Abcam), Phospho-Paxillin Y31  (ab4832, Abcam), Phospho-Paxillin Y118  (2541, Cell 
Signalling), Paxillin (610051, BD transduction laboratories), Zyxin (307011, SYSY), FAK 
(C-20, sc-558, Santa Cruz), Vinculin (ab18058, Abcam), VASP (610447, BD 
transduction laboratories), Parvin (4026, Cell Signalling Technology), CrkII 
(SAB4500470, Sigma) and CrkL (sc-365092, Santa Cruz) or anti-KSHV TK (K1-
A12)(mAb, Stevenson lab).    
 
Primary antibodies were detected with either Alexa Fluro 568 goat anti-rabbit or Alexa 
Fluro 568 donkey anti-mouse (Invitrogen).  Actin was stained with Alexa568-conjugated 
Phalloidin (Invitrogen). MuHV-4 proteins were stained using mAbs 3F7 (glycoprotein, 
gN) (May et al, 2005), MG-12B8 (capsid, ORF65) (Gillet et al, 2006), PG-8A7 (Large 
subunit of RNR, ORF61)(Gill et al, 2010) and BN-6C12 (Tegument component, ORF75c) 
(Gaspar et al, 2008).  Stained cells were mounted in ProLong Gold anti-fade reagent 
with DAPI (Invitrogen).  For time-lapse imaging, live cells grown on iwaki glass based 
dishes (VWR) housed in a heated incubation chamber with constant CO2. All images 
and contraction movies were captured using either a Leica SP2 Confocal microscope.   
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Viruses   
ORF21 flanking sequences were amplified by PCR to incorporated required restriction 
sites, LHS flank coordinate positions 31441-32879 and RHS flank 34054-35931 (based 
on genome sequence AF105037).  The LHS flank was cloned into pSP73 using 
incorporated BglII and EcoRI restriction sites, generating pSP73-LHSfl.  The GFP-
KSHV-TK (WT or Y3F mutant) cassette from pEGFPC2-KSHV TK was digested with 
Eco47III and SalI and cloned into pSP73-LHSfl.  The RHS flank was cloned into the 
resultant pSP73-LHSfl.-GFP-KSHV-TK plasmid, generating pSP73-LHSfl.-GFP-KSHV-
TK-RHSfl.  Flanked GFP-KSHV-TK was amplified and sub-cloned blunt into pST76-SR 
shuttle vector.  The GFP-KSHV-TK coding sequence was then recombined into MuHV-4 
BAC ORF21 locus by standard protocols (Adler et al, 2000). The MHV-68 BAC (MuHV-4 
[g-KSHV-TK) was reconstituted into infectious virus by transfection into BHK-21 cells 
using TransIT-LT1 (Mirus). The loxP-flanked BAC cassette was removed by passaging 
the virus through 3T3-CRE cells.  All virus stocks were grown in BHK-21 cells. Cell 
debris was pelleted by low-speed centrifugation (1,000xg, 3 mins) and virions were 
recovered from the supernatants by high-speed centrifugation (38,000xg, 90 mins), and 
stored at -70°C. Viruses were titered by plaque assay on BHK-21 cells (de Lima et al, 
2004).  rKSHV.219/Vero cells (a generous gift from  Professor J. Vieira, and kindly 
supplied by Professor D. Blackbourn) (Vieira & O'Hearn, 2004), were lytically activated 
using 3mM sodium butyrate. Y-27632 (20µM) was added 10h after induction and 
maintained through-out the experiment.  KSHV-lyt virus, a generous gift of Professor W. 
Brune, was propagated in hTERT-RPE1 cells as previously described (Budt et al, 
2011).  Filtered virus supernatants were to infect HeLa cells for 30h in the presence or 
absence of 20µM Y-27632.  
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Immunoprecipitation and immunoblotting   
Transfected or infected cells were lysed (20 min, 4°C) in 10mM Tris, pH 7.6, 150mM 
NaCl, 5mM EDTA, 10% Glycerol, 1% Triton X100, 1 mM phenylmethylsulfonyl fluoride, 
1mM Na3V04, 1mM NaF, plus Complete protease inhibitors (Roche Diagnostics).
  
Insoluble debris was removed by centrifugation (13,000 x g, 15 min/4oC). For 
immunoprecipitation studies 1g of antibody specific to FAK (C-20) (sc-558, Santa 
Cruz), CrkII (610035, BD Transduction laboratories), CrkL (B-1, sc-365092, Santa Cruz), 
the p85 subunit of PI3-kinase (06-195, Millipore), GFP (ab290, Abcam) or mCherry 
(M11217, Invitrogen) were incubated with pre-cleared cell lysates o/n at 4°C with 
constant rotation, followed by incubation with Protein A/G UltraLink Resin (Thermo-
Scientific) 2 h at 4°C with rotation.  The resin was pelleted and washed 5x in cell lysis 
buffer minus SDS and Sodium deoxycholate, and further washed using 50mM Hepes, 
pH7.4, 150 mM NaCl, 1% Triton X100, 10% Glycerol and precipitated proteins eluted by 
heating (95°C, 5 min) in Laemmli's buffer, resolved by SDS-PAGE, and transferred to 
PVDF membranes.  The membranes were then probed for either FAK (C20 antibody), 
CrkII, CrkIIY221 (34915S, Cell Signalling), CrkL, CrkLY207 (3181S, Cell Signalling), 
PI3K-p85, mCherry or GFP (mAb JL-8, Clontech), Src (mAb GD11, Millipore) or Paxillin 
(610051, BD transduction laboratories).  For siRNA depletion studies the Actin mAb AC-
40 (Sigma) was also used.  Primary antibodies were detected using either polyclonal 
rabbit anti-Mouse (Dako), or horseradish peroxidase-conjugated- anti-rabbit Ig (GE 
Healthcare UK), followed by enhanced chemiluminescence substrate development 
(APBiotech). Phospho-Tyrosine was detected using PY99 and MuHV-4 TK with mAb 
CS1-4A5 (May et al, 2008). 
 
Expression and Purification of GST-fusion proteins, and in vitro kinase assays. 
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BL21 (DE3) Rosetta cells containing pGEX4T1-EBV-TK, MuHV-4–TK, KSHV-TK, KSHV-
TK-DEAD or pOPHT-CrkII (His tagged) were grown overnight at 37oC.  The next day the 
bacterial culture was split 1: 10, grown initially for 90min.  Expression was induced by 
the addition of 0.4 mM IPTG for 3 h at 37oC.  The bacteria were resuspended in lysis 
buffer (150 mM NaCl, 50 mM Tris, pH 7.4, 1% Triton X-100, plus PMSF and Protease 
inhibitors), incubated on ice for 2 h and sonicated.  The lysates were clarified by 
centrifugation and incubated with either glutathione sepharose (for GST-TK 
preparations) or Ni-NTA Agarose (for His-CrkII) for 1 h at 4oC with rotation.  The beads 
were washed four times in lysis buffer and fusion proteins eluted using 100 mM 
glutathione (for GST fusions) or 250 imidazole (for His-CrkII) in 50 mM Tris, pH 8.8, 200 
mM NaCl.  The eluted fusion protein were dialysed overnight against 1X PBS and stored 
at –70oC until required.  Dephosphorylation assay: GST fusion proteins were incubated 
with reaction buffer (25mM HEPES, pH 7, 50mM Nacl, 2.5mM EDTA, 2.5mM DTT)  plus 
PTP1B (539735, Calbiochem) and incubated at 30oC for 30 m.  Samples were 
extensively washed post incubation if used in subsequent kinase reactions. Kinase 
assay:  GST fusion proteins were incubated with kinase reaction buffer (10 mM HEPES, 
pH 7.7, 75 mM NaCl, 5 mM MgCl2, 0.5 mM DTT and incubated at 30
oC for 30 m.  The 
reactions were stopped by the addition of 2X laemmli sample buffer and analysed by 
western blotting.  
 
Mass spectrometry 
Partially purified GST-KSHV-TK was run on a coomassie gel, tryptic digested and the 
fractionated peptides were analysed by LC-MS/MS to map phosphorylated peptides.  
MS/MS analysis was completed by Cambridge Centre for Proteomics Core Services 
(http://www.bioc.cam.ac.uk/uto/deery.html).  The identity of each peptide and 
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phosphorylation sites was determined using Mascot as well as manual interpretation of 
the spectra.  
 
Statistical Analysis 
Data are presented as mean ± standard error of the mean and were analyzed by 
Student’s t test using Prism 6.0 (GraphPad Software, CA). A p value of <0.05 was 
considered statistically significant. 
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Figure legends  
 
Figure 1.  KSHV-TK induces cell contraction and blebbing. 
A. Live cell imaging reveals that expression of GFP-KSHV-TK but not GFP induces 
contraction of HeLa cells (See Movies 1 and 2).  The time from the start of imaging is 
indicated above each panel and the scale bars = 18 µm.  Quantification of GFP-KSHV-
TK induced cell contraction.  The graphs show cell area (m2) of cells expressing the 
indicated protein and error bars represent SEM from 3 independent experiments in 
which n = 224 for GFP and n = 203 for GFP-KSHV-TK.  *** indicates P < 0.001. B.  
Phase images taken from Movie 3 illustrating GFP-KSHV-TK induced blebbing of 
contracted cells. The time from the start of imaging is indicated above each panel and 
the scale bars = 18 µm.  C.  Scanning electron micrographs of HeLa cells expressing 
GFP or GFP-KSHV-TK. D.  Immunofluoresence images illustrating the association of 
GFP-KSHV-TK, but not GFP, with actin stress fibres.  Scale bars = 10 µm.  
 
Figure 2.  KSHV-TK induces disruption of the integrity of focal adhesions.  
A.  Co-expression of GFP-RhoN19 but not GFP inhibits RFP-KSHV TK induced cell 
contraction. Graphs represent cell area (m2) of KSHV-TK, RhoN19 or KSHV-TK and 
RhoN19 expressing cells.  Error bars represent SEM from 3 independent experiments, 
n= 204 for KSHV-TK, n= 223 for RhoN19 and n=189 for KSHV-TK and RhoN19. B. 
GFP-KSHV-TK induced cell contraction does not occur in cells treated with the ROCK 
and Myosin II inhibitors Y-27632 and Blebbistatin respectively. Error bars represent SEM 
from 3 independent experiments, n= 213 for DMSO, n= 189 for Y-27632 and n= 245. C.  
Immunoblot analysis of Rhotekin pulldown (P.D.) assays reveals that GFP-KSHV-TK 
increases the level of GTP-bound RhoA (GTP-RhoA).  Actin is included as a loading 
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control and the input lysates are indicated. D. GFP-KSHV-TK but not GFP induces the 
loss of phospho-tyrosine, phospho-FAK Y925 and phospho-Paxillin Y31 epitopes from 
focal adhesions.  All scale bars represent 20 µm and *** indicates P < 0.001.  
 
Figure 3.  Viral expressed KSHV-TK induces cell contraction and loss of focal 
adhesions.  
A. A schematic illustrating the BAC strategy used to generate a recombinant MuHV-4 
virus (MuHV-4 [g-KSHV-TK]) in which the endogenous MuHV-4 TK is exchanged for 
GFP-KSHV-TK.  B.  Immunoblot analysis of BHK cells infected with MuHV-4, MuHV-4 
[g-KSHV-TK], or uninfected using antibodies against phospho-tyrosine (p-Tyr), GFP, 
MuHV-4 TK, ORF17 (capsid) and glycoprotein N. C. Immunofluorescence analysis of 
MuHV-4 and MuHV-4 [g-KSHV TK] infected cells with the indicated antibodies reveals 
GFP-KSHV-TK expressed in the context of lytic infection (MuHV-4 [g-KSHV-TK]) 
induces the loss of phospho FAK Y925 and Paxillin Y31 from focal adhesions.  White 
arrowheads indicate examples of infected cells expressing GFP-KSHV-TK or GFP 
(indicating WT MuHV-4 infection, BAC+ virus). D. Immunofluorescence analysis reveals 
that GFP-KSHV-TK expressed in the context of lytic infection (MuHV-4 [g-KSHV TK]) 
does not alter focal adhesion integrity (Paxillin) in the presence of of the ROCK inhibitor, 
Y-27632. E. Immunofluorescence analysis of Paxillin in the lytically induced 
rKSHV.219/Vero cell line in the presence of absence of Y-27632. All scale bars = 20 µm.  
 
Figure 4.  The kinase activity of KSHV-TK is required to disrupt focal adhesions  
A.  Cellular localisation and Immunoblot analysis of phospho-tyrosine (upper panel) and 
GFP (lower panel) in cells expressing wild type or kinase Dead GFP-KSHV-TK. B. 
Scanning electron micrographs of HeLa cells expressing GFP or GFP-KSHV-TK-DEAD. 
C.  Immunofluoresence analysis of HeLa cells expressing GFP-KSHV-TK-DEAD (white 
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arrow heads) with the indicated phospho antibodies.  D.  Immunofluoresence images of 
the localization of FAK and Zyxin in HeLa cells expressing GFP-KSHV-TK-DEAD (white 
arrow heads).  E. Purified recombinant GST-EBV-TK, GST-MuHV-4 and GST-KSHV-TK 
immunoblotted for phosphotyrosine and GST following a sequental dephosphorylation 
and kinase reaction. F. Purified recombinant GST-KSHV-TK and GST-KSHV-TK-
KINASE-DEAD immunoblotted for phosphotyrosine and GST.  G. Immunoblot analysis 
demonstrating that the N-terminus of KSHV-TK is only auto-phosphorylated by the 
kinase domain in cis.  All scale bars = 20 µm.  
 
Figure 5.  The activity of KSHV-TK depends on tyrosine 65 and 85 phosphorylation  
A. Immunoblot analysis of N-terminal deletions of KSHV-TK demonstrates that the first 
100 amino acids are required for tyrosine phosphorylation. B. Immunoblot analysis 
reveals that mutation of tyrosine 65, 85 and 120 ablates tyrosine phosphorylation of the 
KSHV-TK. C-E. Immunofluorescence analysis with the indicated antibodies reveals that 
mutation of tyrosines 65, 85 and 120 to phenylalanine abrogates the ability of GFP-
KSHV-TK to induce loss of phospho-tyrosine epitopes, phospho-Paxillin and phospho-
FAK from focal adhesions. F  Immunoblot analysis of level of GTP-bound and total RhoA 
in cells expressing the indicated GFP-tagged KSHV-TK proteins. G. 
Immunofluorescence analysis reveals that localization of paxillin at focal adhesions is 
uneffected by KSHV-TK-Y3F expressed in the context of lytic infection.  Scale bars = 20 
µm.  
 
Figure 6.  The disruptive activity of KSHV-TK is dependent on FAK and Paxillin 
A. Immunoblot analysis reveals that GFP-KSHV-TK WT, Y2F and Y3F but not GFP-
KSHV-TK-DEAD associates with FAK.  B. GFP-KSHV-TK does not displace Paxillin or 
Zyxin from focal adhesions (white arrow heads) or induce contraction in the absence of 
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FAK.  C. GFP-KSHV-TK does not induce loss zyxin and p-Tyr from focal adhesions or 
contraction of HeLa cells depleted of paxillin. Error bars represent SEM from 3 
independent experiments, n= 196 for mock siRNA and n= 229 for paxillin siRNA and *** 
indicates P < 0.001. Scale bars = 20 µm. 
  
Figure 7. Phosphorylated tyrosine 65/85 interact with Crk family members  
A. A schematic representation of the Crk SH2 consensus binding motifs in KSHV-TK. B. 
Immunoblot analysis of GFP antibody immunoprecipitates reveals that GFP-KSHV-TK 
but not Y2F or GFP associates with CrkI, II and L. C. Immunofluorescence analysis 
reveals CrkII associates with GFP-KSHV-TK but not the Y2F mutant. D. Immunoblot 
analysis of RFP antibody immunoprecipitates reveals that RFP-KSHV-TK specifically 
associates with the SH2 domain of CrkII and CrkL.  E. Immunofluorescence analysis of 
phosphotyrosine epitopes in cells expressing GFP-CrkII SH2, GFP-CrkL SH2, RFP-
KSHV-TK or a combination of CrkII/LSH2 and RFP-KSHV-TK. Arrow heads represent 
contracted KSHV-TK expressing cells. The SH2 domains of CrkII or L block KSHV-TK 
induced cell rounding. Scale bars = 20 µm. 
 
Figure 8. KSHV-TK associates with the p85 regulatory subunit of PI3-kinase.  
A. A schematic representation of the p85 regulatory subunit SH2 consensus-binding 
motif of PI3-Kinase in KSHV-TK. B. Immunoblot analysis reveals that GFP-KSHV-TK 
WT and Y2F but not Y120F associates with p85 of PI3-Kinase. C. Immunoblot analysis 
of p85 PI3-Kinase antibody immunoprecipitates reveals that GFP-KSHV-TK and its Y2F 
mutant but not Y120F associates with p85 of PI3-Kinase. D. Immunoblot analysis of 
CrkII and CrkL antibody immunoprecipitates reveals that GFP-KSHV-TK and the p85 
PI3-Kinase associate with CrkII and CrkL. No association is observed with the Y2F, Y3F 
or KINASE-DEAD TK.   E. Tyrosine phosphorylation of CrkII and CrkL is only up 
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regulated in cells expressing GFP-KSHV-TK. F. Immunoblot analysis reveals that 
recombinant His-CrkII binds to and is phosphorylated by KSHV-TK but not the Y2F or 
Y3F mutants.  
 
Supplementary Figures 
Figure S1 
A. Immunofluoresence images showing the localization of GFP and GFP-KSHV-TK in 
COS and BHK cells. B. GFP-HSV1-TK does not induce cell contraction or loss of 
phospho-tyrosine and phospho-paxillin Y31 epitopes from focal adhesions. C. 
Transmission electron micrographs of HeLa cells expressing GFP or GFP-KSHV-TK. D. 
Treatment of HeLa cells with the cell-permeable caspase inhibitor, Z-VAD-FMK does not 
inhibit GFP-KSHV-TK induced cell contraction. E. GFP-KSHV-TK but not GFP induces 
the formation of actin stress fibres and cell rounding. Quantification of GFP-KSHV-TK 
induced cell contraction.  The graph shows the percentage of cells with flattened 
morphology (Flat), flattened morphology with central actin stress fibers (Flat + SF), and 
rounded morphology calculated from 3 independent experiments in which n= 215 for 
GFP and n= 218 for GFP-KSHV-TK. Scale bars = 20 µm. 
 
Figure S2 
A. Immununofluoresence images showing that Y-27632 and Blebbistatin treatment does 
not induce cell contraction or loss of phosphotyrosine, phospho-FAK-Y397, Y925 and 
phospho-paxillin-Y31 epitopes from focal adhesions. B. GFP-KSHV-TK but not GFP 
leads to a loss of the phospho-FAK Y397/Y861 and phospho-Paxillin Y118 signals at 
focal adhesions. C. The graphs represent the total cell fluorescence when staining for 
phospho-Paxillin Y31 or phospho-FAKY925 in cells expressing GFP or GFP-KSHV-TK. 
Only transfected cells were quantified. The error bars represent SEM from 3 
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independent experiments in which n= 123 for GFP and n= 126 for GFP-KSHV-TK when 
staining for phospho-Paxillin Y31 and phospho-FAKY925. Immunoblot analysis showing 
that GFP-KSHV-TK but not GFP leads to reduced Paxillin-Y31 and FAK-Y925 
phosphorylation. Scale bars = 20 m. 
 
Figure S3 
A. GFP-KSHV-TK induces the loss of FAK, Paxillin and Zyxin from focal adhesions. 
White arrowheads indicate cells expressing GFP-KSHV-TK. B. Expression of GFP-
KSHV-TK but not GFP leads to a loss of Parvin, VASP and Vinculin from focal 
adhesions. C. Expression of untagged KSHV-TK or RFP-KSHV-TK induces the loss of 
GFP-FAK from focal adhesions. Scale bars = 20 m.  
 
Figure S4   
A. HeLa cells infected with MuHV-4 or MuHV-4 [g-KSHV-TK] labelled with the indicated 
antibodies reveals that both viruses express early and late lytic proteins. B. 
Immunofluorescence analysis of phosphotyrosine staining in HeLa cells infected with 
KSHV-lyt in the presence of absence of Y-27632. Scale bars= 20 m.   
 
Figure S5 
GFP-KSHV-TK-DEAD does not induce loss of paxillin, phospho-paxillin (Y118), Parvin, 
VASP or Vinculin from focal adhesions. Scale bars = 20 µm. 
 
Figure S6 
A. Immunoblot analysis of Y to F mutants demonstrates that Y65 and Y85 of KSHV are 
phosphorylated. B. Immununofluoresence images showing that the Y2F mutant does not 
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induce cell contraction or loss of phosphotyrosine epitopes from focal adhesions. C. 
Immununofluoresence images showing that the Y2F mutant does not induce loss of 
phospho-Paxillin Y31 or phospho-FAK Y925 epitopes from focal adhesions. D. 
Expression of GFP-KSHV-TK but not GFP induces contraction of zyxin labelled FAK+/+ 
cells. Scale bars = 20 m.  
 
Figure S7 
Partially purified GST-KSHV-TK fractionated and analysed by LC-MS/MS to map 
phosphorylated peptides.  KSHV-TK showing auto-phosphorylation of tyrosine residues 
65, 85 and 120. The identity of each peptide and phosphorylation sites is shown in the 
manual interpretation of the spectra.  
 
Supplementary Movies 
 
Movie S1. The movie shows GFP-KSHV-TK (top panel) induced contraction of a HeLa 
cell in phase contrast (bottom panel) over a period of 2140s. The movie starts 16 hours 
after the cell was first transfected with GFP-KSHV-TK. 
 
Movie S2. The movie shows that GFP (top panel) does not induce contraction of HeLa 
cells in phase contrast (bottom panel) over a 1138s. The movie starts 16 hours after the 
cells were first transfected with GFP. 
 
Movie S3. A phase contrast movie of a HeLa cell undergoing GFP-KSHV-TK induced 
contraction and blebbing over a period of 620s. The movie starts 18 hours after the cells 
were first transfected with GFP-KSHV-TK. 
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